Key Highlights

  • Revenues were USD 759 thousand, compared with USD 316 thousand.
  • Net loss was USD 15.39 million, compared with USD 6.13 million.
  • Loss per share was USD 0.85, compared with USD 0.65.
  • Acquired in-process Research and Development was USD 10.92 million.

Pluri (NASDAQ:PLUR) reported revenues of USD 759 thousand for its fiscal first quarter of 2027, which ended September 30, 2026, compared with USD 316 thousand in the prior-year quarter. Gross Profit was USD 420 thousand, compared with USD 115 thousand.

The net loss was USD 15.39 million, compared with USD 6.13 million, and basic and diluted net loss per share was USD 0.85, compared with USD 0.65.

Operating Results

Cost of revenues was USD 339 thousand, compared with USD 201 thousand. Research and development expenses were USD 2.83 million, compared with USD 3.96 million, and the quarter included acquired in-process research and development of USD 10.92 million related to the Fishway transaction. Research and development expenses, net, were USD 13.67 million, compared with USD 3.93 million.

General and administrative expenses were USD 2.32 million, a decrease of 8% from USD 2.53 million. The operating loss was USD 15.57 million, compared with USD 6.35 million.

Other financial income, net, was USD 415 thousand, compared with USD 439 thousand, and interest expenses related to the Loan were USD 226 thousand, compared with USD 229 thousand. The net loss attributed to non-controlling interest was USD 5.00 million, compared with USD 282 thousand, and the net loss attributed to shareholders was USD 10.39 million, compared with USD 5.85 million.

Balance Sheet

Cash and cash equivalents were USD 3.46 million, compared with USD 3.53 million at June 30, 2026, and short-term bank deposits were USD 4.22 million, compared with USD 4.28 million. Restricted cash was USD 28 thousand, compared with USD 29 thousand, and customer receivables, net, were USD 372 thousand, compared with USD 87 thousand.

Total Assets were USD 24.93 million, compared with USD 24.88 million. The Cash Flow Statement reports cash and cash equivalents of USD 3.46 million, compared with USD 4.26 million, and long-term restricted bank deposits of USD 1.04 million, compared with USD 909 thousand. It also reports restricted cash of USD 28 thousand, compared with USD 428 thousand, in that statement.

Liquidity and Business Description

The filing states that, according to management estimates, the company has sufficient resources to meet its operating obligations for less than three months from the issuance date of the interim financial statements.

The company describes itself as a biotechnology company leveraging its proprietary three-dimensional cell expansion platform, supported by an in-house, industrial-scale cell Manufacturing Facility that operates in accordance with Good Manufacturing Practice standards on a self-declared basis. The filing also states that on April 29, 2020 its German Subsidiary entered into a finance contract with the European Investment Bank for a loan of EUR 20 million, and lists a subsequent event dated October 26, 2026 in the notes.

Pluri Fiscal Q1 2027 Earnings: Key Takeaways

Pluri reported fiscal first quarter 2027 revenues of USD 759 thousand, a net loss of USD 15.39 million and a loss per share of USD 0.85. The quarter included USD 10.92 million of acquired in-process research and development.